Study guide
3.3 Pneumonia & Lower Respiratory Tract Infections
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
3.3 Pneumonia & Lower Respiratory Tract Infections
Key Takeaways Explain This Topic AI
Streptococcus pneumoniae is the most common causative organism of community-acquired pneumonia (CAP), while distinctive atypical pathogens present with characteristic extrapulmonary features: Mycoplasma (erythema multiforme, cold agglutinins), Legionella (travel, hotel water tanks, hyponatraemia, diarrhoea, deranged transaminases), Chlamydia psittaci (psittacine birds), and Staphylococcus aureus (cavitating lesions post-influenza).
The CURB-65 prognostic score stratifies mortality risk based on Confusion (AMTS <= 8), Urea > 7.0 mmol/L, Respiratory rate >= 30/min, Blood pressure (SBP < 90 or DBP <= 60 mmHg), and Age >= 65 years.
Empirical antimicrobial selection in CAP is governed by CURB-65 severity: Score 0-1 low risk (oral amoxicillin or doxycycline at home), Score 2 moderate risk (hospital admission with oral/IV amoxicillin plus a macrolide), and Score 3-5 high risk (urgent hospital admission, consider ICU, IV co-amoxiclav plus IV clarithromycin).
Hospital-acquired pneumonia (HAP, developing > 48 hours post-admission) is dominated by Gram-negative bacilli (Enterobacterales and Pseudomonas aeruginosa) and Staphylococcus aureus, requiring broad-spectrum antipseudomonal agents such as piperacillin-tazobactam.
Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients (CD4 < 200 cells/uL) causes severe exertional desaturation and bilateral perihilar ground-glass infiltrates; treatment requires high-dose co-trimoxazole and adjunctive systemic corticosteroids when room air PaO2 is < 9.3 kPa.
Last updated: October 2026
3.3 Pneumonia & Lower Respiratory Tract Infections
Pneumonia represents acute infection and inflammation of the lung parenchyma, producing alveolar consolidation and systemic inflammatory response. In the United Kingdom and on licensing examinations, clinical competency requires distinguishing typical from atypical organisms, calculating prognostic scores (CURB-65), selecting appropriate empirical antimicrobials, and managing opportunistic and nosocomial infections.
1. Community-Acquired Pneumonia (CAP): Pathogen Spectrum
Community-acquired pneumonia refers to acute pneumonia developing in individuals who have not been hospitalized or resided in a healthcare facility within the preceding 14 days.
Typical Pathogens
Streptococcus pneumoniae (Pneumococcus):
Accounts for 50 – 60 % 50\text{--}60\% 50 – 60% of all bacterial CAP cases.
Classically presents with abrupt high fevers, rigors, pleuritic chest pain, tachypnoea, and rust-coloured sputum.
Radiograph shows dense lobar consolidation with air bronchograms. Severe disease occurs particularly in asplenic patients, older adults, and individuals with chronic organ failure.
Haemophilus influenzae:
Common cause of pneumonia and purulent bronchitis in patients with underlying COPD, bronchiectasis, and chronic smoking.
Moraxella catarrhalis:
Frequently colonizes and infects elderly patients and individuals with chronic structural lung disease.
Atypical Organisms & High-Yield Clinical Associations
Atypical pathogens lack a rigid peptidoglycan cell wall (inherently resistant to beta-lactams) or replicate intracellularly, producing systemic extrapulmonary manifestations:
Mycoplasma pneumoniae:
Common in young adults, school-aged children, and university dormitory outbreaks.
Insidious onset with prolonged dry cough, prominent headache, sore throat, and arthralgias.
Extrapulmonary Hallmarks: Erythema multiforme (targetoid lesions), autoimmune haemolytic anaemia mediated by cold agglutinins (IgM antibodies) , Stevens-Johnson syndrome, and neurological syndromes (Guillain-Barré, transverse myelitis).
Legionella pneumophila:
Transmitted by inhaling contaminated aerosolized water droplets from hotel air conditioning towers, spa pools, or hospital plumbing systems.
Rapidly progressive pneumonia with high fevers and relative bradycardia (Faget's sign).
Extrapulmonary Hallmarks: Profuse watery diarrhoea , abdominal pain, marked encephalopathy/confusion, severe hyponatraemia (due to renal sodium wasting or SIADH), and deranged liver transaminases.
Diagnosis & Treatment: Urinary antigen test (detects serogroup 1); treated with clarithromycin or levofloxacin .
Chlamydia psittaci (Psittacosis):
History of close contact with psittacine birds (parrots, parakeets, cockatoos) or poultry.
Features splenomegaly, high fever, epistaxis, and bilateral interstitial shadowing. Treated with doxycycline .
Coxiella burnetii (Q Fever):
Contact with livestock (cattle, sheep, goats) during calving or lambing seasons.
Manifests as acute pneumonia, culture-negative endocarditis, or granulomatous hepatitis.
Staphylococcus aureus (Post-Viral Secondary Bacterial Pneumonia):
Typically supervenes during or following recovery from acute influenza virus infection.
Causes rapid, necrotizing cavitating pneumonia with multiple abscesses, pneumatoceles , and high mortality. Requires treatment with IV flucloxacillin or co-amoxiclav (vancomycin/linezolid if MRSA is suspected).
2. Risk Stratification: The CURB-65 Score
The British Thoracic Society (BTS) and NICE recommend the CURB-65 score to stratify 30-day mortality risk and guide admission decisions in adults with CAP.
Criteria Item Clinical Parameter Threshold Defining 1 Point
C Confusion Abbreviated Mental Test Score (AMTS) ≤ 8 \le 8 ≤ 8 , or new disorientation in person, place, or time
- U Urea Serum urea > 7.0 mmol/L > 7.0\text{ mmol/L} > 7.0 mmol/L (reflects dehydration and catabolism)
- R Respiratory Rate Respiratory rate ≥ 30 breaths/min \ge 30\text{ breaths/min} ≥ 30 breaths/min
B Blood Pressure Systolic BP < 90 mmHg \text{BP} < 90\text{ mmHg} BP < 90 mmHg OR Diastolic BP ≤ 60 mmHg \text{BP} \le 60\text{ mmHg} BP ≤ 60 mmHg
- 65 Age Age ≥ 65 years \ge 65\text{ years} ≥ 65 years
- Scoring Tiers and Clinical Disposition
Score 0 to 1 (Low Risk - Mortality < 3 % < 3\% < 3% ):
Suitable for outpatient home management.
Provide oral antibiotic therapy, rest, hydration, and clear safety netting.
Score 2 (Moderate Risk - Mortality ∼ 9 % \sim 9\% ∼ 9% ):
Inpatient hospital admission indicated.
Short inpatient stay or closely monitored outpatient ambulatory care with dual oral/IV antimicrobial therapy.
Score 3 to 5 (High Risk - Mortality 15 – 40 % 15\text{--}40\% 15 – 40% ):
Urgent hospital admission required.
Immediately evaluate for critical care unit (HDU or ICU) admission, particularly if multi-lobar consolidation or refractory hypoxaemia is present.
Note
In community general practice without immediate biochemistry access, the CRB-65 score (omitting the urea measurement) is utilized: Score 0 = home management; Score 1–2 = consider hospital referral; Score 3–4 = urgent hospital admission.
3. Empirical Antimicrobial Regimens for CAP (NICE Guidelines)
Antibiotic therapy should be initiated within 4 hours of arrival in hospital (or within 1 hour if sepsis or septic shock is present):
CURB-65 Severity Preferred First-Line Antibiotic Regimen Penicillin Allergy Alternative
Low Severity (Score 0-1) Amoxicillin 500 mg 500\text{ mg} 500 mg TDS oral for 5 days Doxycycline 200 mg 200\text{ mg} 200 mg stat then 100 mg 100\text{ mg} 100 mg OD , or Clarithromycin 500 mg 500\text{ mg} 500 mg BD
Moderate Severity (Score 2) Amoxicillin 500 mg 500\text{ mg} 500 mg TDS oral/IV PLUS Clarithromycin 500 mg 500\text{ mg} 500 mg BD oral/IV for 5 days Doxycycline 200 mg 200\text{ mg} 200 mg stat then 100 mg 100\text{ mg} 100 mg OD , or Clarithromycin 500 mg 500\text{ mg} 500 mg BD (erythromycin in pregnancy)
High Severity (Score 3-5) Co-amoxiclav 1.2 g 1.2\text{ g} 1.2 g TDS IV PLUS Clarithromycin 500 mg 500\text{ mg} 500 mg BD IV ; total course 5 days, then stop unless not clinically stable or a specific pathogen needs longer (NICE NG138) Levofloxacin 500 mg 500\text{ mg} 500 mg BD (consult a microbiologist; add MRSA cover only if suspected or confirmed)
Essential Diagnostic Investigations in Inpatient CAP
Moderate to High Severity: Sputum microscopy and culture, blood cultures (before antibiotics), pneumococcal and Legionella urinary antigen tests , full blood count, renal and liver function panels, CRP, and arterial blood gas.
Repeat Radiography: NICE CG191 advises not routinely offering a follow-up chest X-ray to people whose symptoms have resolved. Consider one (usually about 6 weeks after treatment) for persistent symptoms or a higher risk of underlying lung cancer, such as smokers and people over 50.
4. Hospital-Acquired Pneumonia (HAP)
Hospital-Acquired Pneumonia is defined as pneumonia developing > 48 hours > 48\text{ hours} > 48 hours after hospital admission that was neither present nor incubating at admission.
Microbiology & Resistance
Unlike CAP, HAP is dominated by nosocomial Gram-negative bacilli and hospital-adapted pathogens:
- Pseudomonas aeruginosa
- Klebsiella pneumoniae and other Enterobacteriaceae ( E . coli E.\text{ coli} E . coli , Proteus)
- Staphylococcus aureus (including Methicillin-Resistant S . aureus S.\text{ aureus} S . aureus [MRSA])
- Acinetobacter species in ventilated intensive care patients (VAP)
- Empirical Management
Mild / Non-Severe HAP (Early Onset): Oral co-amoxiclav 625 mg 625\text{ mg} 625 mg TDS (or doxycycline/ceftriaxone) for 5 days.
Severe HAP / High Risk of Resistance (Late Onset > 5 days > 5\text{ days} > 5 days , ICU, Prior Antibiotics): Broad-spectrum intravenous antipseudomonal therapy with Piperacillin-tazobactam (Tazocin) 4.5 g 4.5\text{ g} 4.5 g TDS IV , ceftazidime 2 g 2\text{ g} 2 g TDS IV, or meropenem 1 g 1\text{ g} 1 g TDS IV. Add vancomycin or linezolid if MRSA is suspected.
5. Aspiration Pneumonia
Aspiration pneumonia results from the inhalation of oropharyngeal secretions or gastric contents into the lower respiratory tract, triggering a chemical pneumonitis and secondary polymicrobial bacterial infection.
Risk Factors
Depressed conscious level (acute stroke, head trauma, general anaesthesia, alcohol or drug intoxication, post-ictal state).
Bulbar or pseudobulbar palsy (motor neurone disease, Parkinson's disease, myasthenia gravis).
Gastro-oesophageal reflux, persistent vomiting, or presence of a nasogastric feeding tube.
Anatomical Localization
Due to gravitational drainage and bronchial anatomy (the right main bronchus is wider, shorter, and more vertical):
Recumbent / Supine Patient: Apical (superior) segment of the right lower lobe or posterior segment of the right upper lobe .
Erect / Sitting Patient: Basilar segments of the right lower lobe .
Microbial Flora and Treatment
Dominated by oral anaerobes ( Peptostreptococcus , Fusobacterium nucleatum , Prevotella , Bacteroides ) alongside oral streptococci and Gram-negative bacilli.
First-Line Antibiotics: Intravenous Co-amoxiclav 1.2 g 1.2\text{ g} 1.2 g TDS (or cephalosporin/ciprofloxacin plus intravenous Metronidazole 500 mg 500\text{ mg} 500 mg TDS for anaerobic coverage).
6. Pneumocystis jirovecii Pneumonia (PCP / PJP)
Pneumocystis jirovecii is an opportunistic fungal pathogen that causes severe, life-threatening pneumonia in immunocompromised individuals—classically patients with HIV infection with CD4 count < 200 cells/ μ L < 200\text{ cells/}\mu\text{L} < 200 cells/ μ L , solid organ transplant recipients, haematological malignancies, or those on prolonged high-dose corticosteroid therapy.
Clinical Triad & Hallmarks
Insidious Progression: Subacute dry, non-productive cough, low-grade fevers, and progressive breathlessness evolving over weeks.
Disproportionate Exertional Desaturation: Chest auscultation is frequently unremarkable, but oxygen saturation plunges dramatically upon minimal exertion (e.g., walking a short distance).
Radiography: Bilateral, symmetrical perihilar ground-glass interstitial infiltrates ("bat-wing" distribution). Normal CXR occurs in up to 10% of cases; high-resolution CT shows diffuse ground-glass attenuation.
Diagnosis & Management
Microbiological Confirmation: Direct visualization of cysts on induced sputum or bronchoalveolar lavage (BAL) using silver stain (Grocott's methenamine silver) or immunofluorescence/PCR.
First-Line Antimicrobial Therapy: High-dose Co-trimoxazole (Trimethoprim-Sulfamethoxazole) given intravenously ( 120 mg/kg/day 120\text{ mg/kg/day} 120 mg/kg/day in 3–4 divided doses) for 21 days.
Indications for Adjunctive Systemic Corticosteroids:
Corticosteroids (oral prednisolone or IV methylprednisolone) must be administered before or simultaneously with co-trimoxazole if moderate-to-severe hypoxaemia is present:
Room air PaO 2 < 9.3 kPa \mathbf{\text{PaO}_2 < 9.3\text{ kPa}} PaO 2 < 9.3 kPa ( < 70 mmHg < 70\text{ mmHg} < 70 mmHg ) , OR
Alveolar-arterial oxygen gradient ≥ 35 mmHg \ge 35\text{ mmHg} ≥ 35 mmHg .
Mechanism: Lysis of organisms by antimicrobials causes intense inflammatory alveolar exudation; steroids prevent acute respiratory deterioration and fatal ARDS.